A secondary analysis of a phase 2 trial supports prior observations that MSI-stable colorectal cancer refractory to standard treatment is particularly responsive to immune checkpoint inhibition when there are no liver metastases, leading to the hypothesis that the addition of radiation to liver mets in this setting may improve outcomes. | Chen, JAMA Netw Open 2023
